CM
IONS icon

Castleark Management’s Ionis Pharmaceuticals IONS Stock Holding History

Castleark Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-27,125
Closed -$1.63M – 375
2019
Q3 		$1.63M Buy
+27,125
New +$1.77M 0.07% 224
2015
Q3 		– Sell
-29,625
Closed -$1.71M – 385
2015
Q2 		$1.71M Sell
29,625
-118,038
-80% -$7.51M 0.05% 286
2015
Q1 		$9.4M Sell
147,663
-18,225
-11% -$1.24M 0.23% 141
2014
Q4 		$10.2M Buy
+165,888
New +$8.19M 0.26% 110
2013
Q4 		– Sell
-108,500
Closed -$4.21M – 348
2013
Q3 		$4.21M Buy
+108,500
New +$3.24M 0.12% 184

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Castleark Management's IONS Position: Q4 2019 in Review

Castleark Management sold out of Ionis Pharmaceuticals (IONS) in Q4 2019, closing a stake of 27,125 shares — an estimated $1.63M sold.

Castleark Management first reported a position in IONS in Q3 2013 and held it in 5 quarters. The position peaked at $10.2M in Q4 2014. 390 funds tracked by Wall St. Rank hold IONS as of Q4 2019.

  • Castleark Management reported no remaining Ionis Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Castleark Management sold 27,125 Ionis Pharmaceuticals shares in Q4 2019, an estimated $1.63M.
  • Castleark Management first reported a position in Ionis Pharmaceuticals in Q3 2013 and held it in 5 quarters.
  • Castleark Management's Ionis Pharmaceuticals position peaked at $10.2M in Q4 2014.
  • 390 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2019.

Based on Castleark Management's 13F filing for Q4 2019, filed 14 Feb 2020.